News | March 17, 2023
Jubilant receives additional CAD 23.8 million loan facility for CMO Montreal facility
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
Asthma patients are more likely to have an asthma attack during winter
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
MVUs will provide diagnosis treatment, vaccination, artificial insemination, minor surgical interventions, audio-visual aids and extension services to farmers/animal owners at their doorstep in far flung areas.
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
Global pharmaceutical company having a surgical business concept incepted in Dubai
Subscribe To Our Newsletter & Stay Updated
